Head-to-head · WeighScore
CoreAge Rx vs Tablet Health
The verdict
CoreAge Rx takes it — 91.8/100 to 47.6/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoreAge Rx | Tablet Health |
|---|---|---|
| WeighScore | 91.8/100 | 47.6/100 |
| Grade | A− | C |
| Scorecard rank | #1 | #495 |
| Semaglutide | $149/mo | Not disclosed |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #1 · A−
Strengths
- Flat all-in price with no month-two step-up
- Semaglutide and tirzepatide on one account
- All 50 states, LegitScript-verified
Where it loses points
- Not the cheapest sticker price
- Compounded only
- Pharmacy partner not yet publicly named
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.